Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CFD | P00746 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166372 | 0.94 | POLB (0.48) | POLBKDM4EACHEHTTCFD | |
| SCHEMBL166802 | 0.85 | GAA (0.50) | POLBKDM4EHTTSOS1MAPT | |
| SCHEMBL5154161 | 0.81 | SOS1 (0.45) | KDM4EACHESOS1MAPTLMNA | |
| SCHEMBL167764 | 0.81 | POLB (0.51) | POLBKDM4EACHEHTTMAPT | |
| SCHEMBL19838683 | 0.80 | PRKDC (0.50) | POLBKDM4ECFDSOS1MAPT | |
| SCHEMBL167840 | 0.80 | POLB (0.38) | POLBKDM4EHTTCFDSOS1 | |
| SCHEMBL166131 | 0.80 | KDM4E (0.39) | POLBKDM4EHTTCFDSOS1 | |
| SCHEMBL7417048 | 0.80 | SMN1; SMN2 (0.44) | POLBKDM4EHTTCFDMAPT | |
| SCHEMBL28919524 | 0.80 | POLB (0.57) | POLBKDM4EACHEHTTCFD | |
| SCHEMBL17560071 | 0.79 | TDP1 (0.50) | POLBKDM4EHTTMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494118-B1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-10562910-B2 | Nitrogen-containing tricyclic compounds and uses thereof in medicine | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (HK) | 2020-02-18 | — | — | US | disclosed |
| EP-3494118-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | Sunshine Lake Pharma Co., Ltd. (CN) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169203-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
| WO-2018024224-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-08 | — | — | WO | disclosed |
| US-9365551-B2 | 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2016-06-14 | — | — | US | disclosed |
| EP-2611772-B1 | 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2611772-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028629-A1 | 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562910-B2 | Nitrogen-containing tricyclic compounds and uses thereof in medicine | NR1H4, SLC10A1, SLC10A2 | POLB 2798/4885KDM4E 4829/4885ACHE 2742/4885 |
| US-20130225584-A1 | 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS | LRRK2, PARK7, BRSK2 | POLB 1496/4885KDM4E 1447/4885ACHE 692/4885 |
| US-20190169203-A1 | NITROGEN-CONTAINING TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | NR1H4, SLC10A1, SLC10A2 | POLB 2798/4885KDM4E 4829/4885ACHE 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.